NVCT (STOCKS)
Nuvectis Pharma, Inc. Common Stock
$11.150000
+0.440000 (+4.11%)
Prev close: $10.710000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Ronald E. Bentsur
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $296.10M
- Employees
- 13
- P/E (TTM)
- -8.75
- P/B (TTM)
- 19.98
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.26 | $-0.32 | +0.0562 | +17.77% |
|
Dec 2025 (Q4)
|
$-0.31 | $-0.30 | -0.0065 | -2.14% |
|
Sep 2025 (Q3)
|
$-0.33 | $-0.25 | -0.0775 | -30.69% |
|
Jun 2025 (Q2)
|
$-0.30 | $-0.26 | -0.0399 | -15.34% |
Financial Statements
| Research and Development | $18.58M |
| Operating Income/Loss | -$28.27M |
| Income/Loss From Continuing Operations After Tax | -$27.16M |
| Income/Loss From Continuing Operations Before Tax | -$27.16M |
| Net Income/Loss | -$27.16M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$27.16M |
| Net Income/Loss Available To Common Stockholders, Basic | -$29.59M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $2.43M |
| Preferred Stock Dividends And Other Adjustments | $2.43M |
| Basic Earnings Per Share | -$1.31 |
| Diluted Earnings Per Share | -$1.31 |
| Basic Average Shares | 67,961,288 |
| Diluted Average Shares | 67,961,288 |
| Assets | $25.40M |
| Current Assets | $25.40M |
| Noncurrent Assets | $0.00 |
| Liabilities | $11.18M |
| Current Liabilities | $11.18M |
| Accounts Payable | $4.70M |
| Wages | $6.45M |
| Other Current Liabilities | $36.00K |
| Noncurrent Liabilities | $0.00 |
| Equity | $14.22M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $14.22M |
| Liabilities And Equity | $25.40M |
| Net Cash Flow From Operating Activities | -$18.35M |
| Net Cash Flow From Operating Activities, Continuing | -$18.35M |
| Net Cash Flow From Investing Activities | $4.73M |
| Net Cash Flow From Investing Activities, Continuing | $4.73M |
| Net Cash Flow From Financing Activities | $13.61M |
| Net Cash Flow From Financing Activities, Continuing | $13.61M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$27.16M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$27.16M |
| Other Comprehensive Income/Loss | $0.00 |